擎科生物推出"siRNA裸序列定制合成服务"，创新实现最快3天交付

Core Insights - Beijing Qingtian Biotechnology Co., Ltd. has launched a "siRNA naked sequence custom synthesis service" aimed at accelerating early research and drug discovery processes by significantly reducing delivery time to 3-4 calendar days [1][8] Group 1: Service Features - The service addresses early-stage research challenges by enabling rapid target validation, high-throughput in vitro screening, candidate sequence evaluation, and preparation for in-depth mechanistic studies [2][3][4] - Delivery time for standard specifications (5 nmol/2 OD) is reduced by approximately 30%-50% compared to industry norms, with the fastest delivery reaching 3 calendar days [5] - Each sequence undergoes strict quality control via mass spectrometry (MS), ensuring consistent knockdown efficiency comparable to conventionally synthesized products [5] - The service offers flexible specifications ranging from micro (5 nmol) to large quantities (1000 nmol), catering to various experimental stages [5] Group 2: Platform Capabilities - The launch of the rapid synthesis service showcases Qingtian's capabilities within its oligonucleotide CRDMO platform, which has over 20 years of technical experience [6] - The platform provides a comprehensive range of services from research-grade synthesis to GMP-compliant active pharmaceutical ingredient production [6] - The ability to compress delivery time to "as fast as 3 calendar days" highlights the company's strong integration capabilities in process optimization and production scheduling, providing a competitive edge in the small nucleic acid drug CRDMO sector [6] Group 3: Market Implications - The rapid development of RNAi therapies and small nucleic acid drugs has increased market demands for speed, quality, and cost in early research tools [8] - The introduction of the "fastest 3 calendar days delivery" service directly addresses the urgent needs of domestic research institutions and new drug development companies, potentially prompting a reevaluation of overall response standards in the R&D supply chain [8]